Guideline Medications for Chronic Diastolic Heart Failure

Primary Therapeutic Approach

The European Society of Cardiology recommends focusing on symptom management with diuretics, blood pressure control with ACE inhibitors or ARBs, heart rate control with beta-blockers, and consideration of SGLT2 inhibitors based on recent evidence, with a strength of evidence level C 1, 2
Diuretics should be used cautiously when fluid overload is present to relieve pulmonary congestion and peripheral edema, with the critical caveat to avoid excessive diuresis that can lower preload excessively and reduce stroke volume and cardiac output in diastolic dysfunction 3, 4, 5
ACE inhibitors may improve relaxation and cardiac distensibility directly, have long-term effects through regression of hypertrophy, and reduce hypertension, with ARBs as an alternative if ACE inhibitors are not tolerated 1, 3, 5
Beta-blockade is recommended to lower heart rate and increase the diastolic filling period, which is particularly important in diastolic dysfunction, with the goal of preventing tachycardia that can worsen symptoms 1, 3, 5
Verapamil-type calcium antagonists may be used to lower heart rate and increase diastolic period, and may lead to functional improvement, particularly in hypertrophic cardiomyopathy 1, 3, 5

In patients with atrial fibrillation, rate control is mandatory, and digitalis glycosides are the first choice for symptomatic patients, with beta-blockade, digitalis glycosides, or combination considered for asymptomatic patients 1, 3, 5
For concomitant hypertension, optimize ACE inhibitors, beta-blockers, and diuretics, and consider adding spironolactone or ARBs if not already present, with second-generation dihydropyridine derivatives as an alternative if unsuccessful 1, 5

Avoid excessive diuresis, as diastolic dysfunction is highly preload-dependent, and over-diuresis can precipitate hypotension and reduced cardiac output 3, 4, 5
Maintain sinus rhythm when possible, as atrial contribution to ventricular filling is critical in diastolic dysfunction, and avoid tachycardia that can significantly worsen symptoms 1, 5

The European Society of Cardiology recommends checking blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, at 3 months, and subsequently at 6-month intervals when using ACE inhibitors 6, 7
If the patient develops intolerable cough or other ACE inhibitor side effects, the European Society of Cardiology suggests switching to an ARB as an alternative, which has significantly fewer side effects while providing similar benefits 6, 8
The European Society of Cardiology advises starting beta-blockers at low doses and titrating gradually to avoid precipitating acute decompensation 7, 9
Loop diuretics or thiazides should always be administered in addition to an ACE inhibitor, never as monotherapy, as recommended by the European Society of Cardiology 6, 7
If GFR < 30 mL/min, the European Society of Cardiology recommends not using thiazides except synergistically with loop diuretics 6, 8

The European Society of Cardiology recommends avoiding potassium-sparing diuretics during ACE inhibitor initiation to prevent hyperkalemia 6, 7, 8
The European Society of Cardiology advises reducing or withholding diuretics for 24 hours before starting ACE inhibitor therapy to avoid excessive hypotension 7, 8

The European Society of Cardiology recommends monitoring blood pressure, renal function (creatinine, GFR), and electrolytes (potassium, sodium) at baseline, 1-2 weeks after dose changes, at 3 months, and every 6 months thereafter 6, 7, 9

The European Society of Cardiology suggests controlling sodium intake when necessary, particularly if fluid retention develops 8
The European Society of Cardiology recommends avoiding excessive fluid intake if heart failure symptoms worsen 8
The European Society of Cardiology advises limiting alcohol consumption 8